BioMaxima S.A.
BMX.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -11.74 | -1.24 | 0.02 | 0.49 |
| FCF Yield | -5.40% | -23.25% | 24.45% | -4.06% |
| EV / EBITDA | 12.61 | 25.05 | 2.71 | 8.84 |
| Quality | ||||
| ROIC | 3.35% | 3.40% | 43.07% | 20.56% |
| Gross Margin | 44.01% | 42.80% | 37.69% | 36.66% |
| Cash Conversion Ratio | -0.50 | 2.72 | 1.03 | -0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -28.38% | -16.05% | 32.67% | 37.40% |
| Free Cash Flow Growth | 85.31% | -160.65% | 689.21% | -320.51% |
| Safety | ||||
| Net Debt / EBITDA | 2.95 | 3.46 | -0.18 | 1.15 |
| Interest Coverage | 1.34 | 1.20 | 73.38 | 52.11 |
| Efficiency | ||||
| Inventory Turnover | 2.19 | 2.10 | 6.99 | 3.57 |
| Cash Conversion Cycle | 190.35 | 182.58 | 62.07 | 143.76 |